Trial Condition(s):

Atrial Fibrillation

Burden of illness in Atrial Fibrillation

Bayer Identifier:

18313

ClinicalTrials.gov Identifier:

NCT02615587

EudraCT Number:

Not Available

Study Completed

Trial Purpose

The overall goal of this retrospective registry study is to investigate the burden-of.illness in atrial fibrillation (AF) in Denmark. Several Danish registries will be utilized to collect information on the diseases epidemiology including incidence and prevalence of AF and stroke as well as a stroke risk stratification of the Danish AF-population, the clinical and economical burden (in terms of direct and indirect cost) of AF and stroke to Danish patients, healthcare providers / healthcare system and society as well as describing treatment patterns with anticoagulant agents and their consequences in terms of stroke, bleeds, death and according cost in a real-life setting.

Inclusion Criteria
-  Primary and secondary diagnosis with AF; 
 -  The base population of AF patients will be identified in the National Patient Registry. For a given period of time (2000-2013, both years inclusive) all patients with a hospital contact (admission, outpatient visit or ER visit) and for whom AF was the primary or secondary diagnosis code (ICD10-code: DI480, DI481, DI482, DI483, DI484, DI489) will be included.
Exclusion Criteria
-  Patients younger than 18 and older than 90 years of age.

Trial Summary

Enrollment Goal
107532
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many locations, Denmark

Status
Completed
 

Trial Design